From TekinHealthHealthcare Tech Field Notes

DeepHealth, a RadNet company, received FDA 510(k) clearance for Chest XRay, formerly ChestView. The computer-aided detection tool finds and localizes suspected lung nodules, consolidation, mediastinal and hilar abnormalities, and pleural abnormalities including pneumothorax. It is reported to be one of the first FDA-cleared chest X-ray AI products built on a foundation model. The company says the CE-marked European version analyzes more than 2.8 million exams a year.

Why it's notable: Foundation-model imaging AI can add new findings faster than single-purpose algorithms. This clearance shows the FDA is accepting that design for one of the most common exams in medicine.

The FDA granted De Novo authorization to Powerful Medical's PMcardio Queen of Hearts, an AI model that reads 12-lead ECGs for signs of urgent acute coronary syndrome, including STEMI and STEMI equivalents, and alerts clinicians to suspected cases. STAT reported the authorization on September 11 and the company announced it on September 15. The company says the model is backed by more than 20 peer-reviewed studies covering over 40,000 patients, found about twice as many heart attacks as standard care with up to five times fewer false positives, and is already used across more than 150 hospital locations, mostly in Europe.

Why it's notable: Many heart attacks caused by a fully blocked artery don't meet standard STEMI criteria on the ECG. A tool that flags them could get more of these patients to the cath lab faster. De Novo authorizations are rare, and this one creates a new FDA device category for AI ECG models that detect acute, life-threatening heart conditions.

The FDA's Digital Health Center of Excellence published a discussion paper on how it might regulate medical devices that use generative AI. The paper sets out a two-axis risk framework: how independently a device acts, and how much harm a wrong output could cause. It also proposes competency-based premarket testing that combines benchmarking with clinical confirmation, and it covers postmarket monitoring, foundation models and agentic systems. Comments are due October 19, 2026, under docket FDA-2026-N-7874. The FDA has not yet authorized any generative AI device.

Why it's notable: This is the clearest signal so far of how the FDA may treat LLM-based clinical tools, including chatbots and agents. Those rules will decide which of these tools can be marketed for clinical use and what evidence vendors must show.

RadNet subsidiary DeepHealth received FDA 510(k) clearance on July 30, 2026 for DeepHealth Breast Ultrasound, software that automates lesion detection, characterization and reporting. In a multi-reader study with 16 U.S. board-certified radiologists, the company reports more than 98% lesion localization accuracy, an 8% gain in cancer-detection sensitivity and a 37% cut in interpretation time. It is commercially available in the U.S., and DeepHealth expects to roll it out across RadNet's imaging centers by year end.

Why it's notable: Breast ultrasound is labor-intensive and highly operator-dependent, and it is used more often for women with dense breasts. A cleared tool that drafts findings and reports could ease radiologist workload in breast imaging.

Johnson & Johnson received FDA de novo authorization on July 22, 2026 for its Ottava robotic surgical system, which builds four robotic arms into the operating table. The authorization covers upper-abdominal and other general surgery procedures including Roux-en-Y gastric bypass, sleeve gastrectomy, cholecystectomy, splenectomy, appendectomy, small bowel resection, fundoplication and hiatal hernia repair. The authorization came about six months after J&J filed. The company says it will launch with select U.S. customers first, and a U.S. trial in inguinal hernia repair is ongoing.

Why it's notable: Ottava is a second major competitor to Intuitive's da Vinci in soft-tissue surgery, after Medtronic's Hugo, which gives hospitals buying robots more choice on price and operating-room footprint.

On June 25, 2026, UpDoc publicly announced the FDA 510(k) clearance (K253281, granted in December 2025) of UpDoc V1.0. It is prescription software that talks with adults with type 2 diabetes by voice or text and adjusts their insulin within limits set by their physician. The company calls it the first FDA-cleared device to use patient-facing large language models. It says the system is deployed at Cleveland Clinic, Allegheny Health Network and UCSF Health, can order follow-up labs and writes its actions into the EHR. It was cleared as a 510(k) with an insulin dosing program as the predicate device, and it is backed by a small Stanford randomized trial published in JAMA Network Open. STAT reported that the CEO would not say whether the language model itself makes the dosing decisions.

Why it's notable: This is the first regulatory path for an AI that talks directly with patients to adjust a drug between visits, and other developers are likely to follow it. It also leaves open how much of the clinical decision the language model makes and how much fixed dosing rules make.

On June 25, 2026, Aidoc said the FDA granted Breakthrough Device Designation to First Read, software that analyzes chest radiographs and writes a draft radiology report for a radiologist to review and sign. The designation covers four life-threatening findings, and the company says the tool is designed to report on more than 100 findings. It is built on Aidoc's CARE foundation model. Breakthrough designation speeds up FDA review but is not a clearance, and First Read is not yet on the market. It is Aidoc's second breakthrough designation in under a year.

Why it's notable: This is one of the first AI tools meant to write the radiology report itself, not just flag a finding, to enter an expedited FDA pathway. That points to how imaging backlogs and report turnaround times may be handled.

Oura introduced its Ring 5 on May 28, 2026, with plans to add a feature that tracks overnight blood pressure patterns and tells users when to see a doctor. The feature shows trends rather than systolic and diastolic readings, and it is sold as a wellness tool without FDA review under the agency's January 2026 wellness guidance. Oura said a separate feature to flag possible hypertension is being studied and will go through the FDA. The launch also added health record import and access to clinicians through Counsel Health and ResMed.

Why it's notable: Clinicians should expect patients to bring in blood pressure trends from rings and watches that no regulator has checked for accuracy. Experts quoted by STAT warned that these unvetted blood pressure features are spreading quickly.

On April 1, 2026, the FDA denied a petition from Sydney-based Harrison.ai. The company wanted developers that already had a 510(k) clearance to be able to market new AI tools in four radiology categories without premarket review, including triage (CADt), detection and diagnosis (CADe/CADx) software and medical image analyzers. The agency said clearing one device does not show that a company's processes will produce safe future devices, and that postmarket monitoring cannot replace premarket review. It pointed developers to predetermined change control plans instead. The FDA finalized the denial in the Federal Register on September 17, 2026.

Why it's notable: New radiology AI tools, and major new versions of them, will still need FDA review before they reach health systems. Buyers should check which software version is actually cleared.

On February 13, 2026, Medtronic announced FDA clearance of Stealth AXiS for spine surgery. The system combines surgical planning, navigation and robotic assistance in one platform. Its LiveAlign segmental tracking lets surgeons watch spinal motion and alignment during surgery without repeated imaging, the company says. Medtronic says the system is built for both hospitals and ambulatory surgery centers. It builds on Medtronic's 2018 purchase of Mazor Robotics and its StealthStation navigation line. The FDA later cleared it for cranial and ENT procedures in March 2026.

Why it's notable: Spine surgery is moving to outpatient centers. A single system that replaces separate navigation and robot units could make robotic spine surgery practical at ambulatory surgery centers, and it sharpens Medtronic's competition with Globus Medical.

On December 3, 2025, Medtronic announced FDA clearance of its Hugo robotic-assisted surgery system for prostatectomy, nephrectomy and cystectomy. The company says these procedures account for about 230,000 US surgeries a year. The clearance was based on the Expand URO study, which Medtronic says met its primary safety and effectiveness endpoints. Hugo was already in use in more than 30 countries, and Medtronic says it expects general and gynecologic surgery indications to follow.

Why it's notable: Hugo is the first multi-port system from a large medtech company to enter the US soft-tissue robotics market dominated by Intuitive's da Vinci. That gives hospitals building robotic urology programs a second option from a major vendor.

Stereotaxis received FDA 510(k) clearance for GenesisX, its next-generation robotic magnetic navigation system. Physicians use it to steer a magnetic-tipped catheter from a computer during ablation for arrhythmias such as atrial fibrillation. Unlike earlier Stereotaxis systems, GenesisX has magnetic shielding built into the unit rather than the room walls, runs on standard power, needs no structural anchoring and has an 80% smaller cabinet. The company says this lets it be installed in existing cath labs without construction.

Why it's notable: Earlier versions needed a lab rebuilt around the robot, which was a big reason few hospitals adopted robotic navigation for ablation. Removing that requirement makes it a practical option for more EP programs.

Distalmotion received FDA 510(k) clearance for its Dexter robotic surgery system in total benign hysterectomy, removal of the ovaries and fallopian tubes, and other gynecologic procedures. It is Dexter's third U.S. indication, after inguinal hernia repair in October 2024 and gallbladder removal in May 2025. The company is targeting hospital outpatient departments and ambulatory surgery centers with a mobile robot that several specialties can share, and it says Dexter has been used in more than 2,000 procedures.

Why it's notable: Hysterectomy is one of the most common gynecologic operations and is moving to outpatient settings. A cheaper, shareable robot cleared for it adds competition to Intuitive's da Vinci for ambulatory surgery centers.